IRVINGTON, NY--(Marketwire - June 29, 2009) - Electro-Optical Sciences, Inc. ("EOS")
(NASDAQ: MELA), a medical technology company focused on the design and
development of MelaFind®, a non-invasive, point-of-care instrument to
assist in the early detection of melanoma, today announced that the
company's shares have been added to the Russell 2000® and Russell 3000®
indexes, effective immediately.
Membership in the Russell 3000, which remains in place for one year, means
automatic inclusion in the Russell 2000 Index as well as the appropriate
growth and value style indexes. Member companies are drawn from the 4,000
largest companies meeting the indexes' criteria as of the end of each May
and are added or deleted annually as the indexes are reconstituted each
"We are pleased to be included in both Russell indexes and believe that
this will bring a more diverse group of shareholders to the stock and may
generate additional attention to the company as MelaFind advances through
the regulatory pathway at the Food and Drug Administration," said Joseph V.
Gulfo, M.D., Chief Executive Officer of EOS.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. According to Russell, an industry-leading $4
trillion in assets currently are benchmarked to them.
About Electro-Optical Sciences
Electro-Optical Sciences is a medical technology company focused on
developing MelaFind®, a non-invasive and objective computer vision system
intended to aid in the early detection of melanoma. EOS designed
MelaFind® to assist in the evaluation of pigmented skin lesions,
including atypical moles, which have one or more clinical or historical
characteristics of melanoma, before a final decision to biopsy has been
rendered. MelaFind® acquires and displays multi-spectral (from blue to
near infrared) digital images of pigmented skin lesions and uses automatic
image analysis and statistical pattern recognition to help identify lesions
to be considered for biopsy to rule out melanoma. For more information on
EOS, visit www.eosciences.com.
This press release includes "forward-looking statements" within the meaning
of the Securities Litigation Reform Act of 1995. These statements include
but are not limited to our plans, objectives, expectations and intentions
and other statements that contain words such as "expects," "contemplates,"
"anticipates," "plans," "intends," "believes" and variations of such words
or similar expressions that predict or indicate future events or trends, or
that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant
uncertainties and changes in circumstances, many of which are beyond our
control. There can be no assurance that our beliefs or expectations will be
achieved. Actual results may differ materially from our beliefs or
expectations due to economic, business, competitive, market and regulatory